Iron sucrose
- Generic Name
- Iron sucrose
- Brand Names
- Velphoro, Venofer
- Drug Type
- Small Molecule
- Chemical Formula
- C12H29Fe5Na2O23
- CAS Number
- 8047-67-4
- Unique Ingredient Identifier
- FZ7NYF5N8L
- Background
Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and those who do not require dialysis. Due to less side effects than iron dextran, iron sucrose is more preferred in chronic kidney disease patients.
- Indication
Iron sucrose is elemental iron as an injection. It replenishes body iron stores in patients with iron deficiency.
- Associated Conditions
- Hyperphosphataemia
The Use of Liposomated Iron After Bariatric Surgery in Patients That Are Receiving Parentheral Therapy With Iron
- Conditions
- Liposomated IronY-de-Roux Gastric By-PassParenteral Iron Therapy
- Interventions
- Drug: Fisiogen Ferro Forte
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2017-04-12
- Target Recruit Count
- 40
- Registration Number
- NCT02390921
- Locations
- 🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain
Bioequivalence Study With Pharmacokinetic Endpoints, Comparing a Single Dose of Iron Sucrose Azad Injection of Azad Pharma Corporation (AG), With a Single Dose of Venofer® Injection of Vifor Corporation (AG) in Healthy Adult Volunteers
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Azad Pharma AG
- Target Recruit Count
- 30
- Registration Number
- NCT02391181
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia
- First Posted Date
- 2013-05-14
- Last Posted Date
- 2014-11-13
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Registration Number
- NCT01852682
A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia
- First Posted Date
- 2013-05-09
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 35
- Registration Number
- NCT01850641
A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
- Conditions
- HyperphosphatemiaHemodialysis
- Interventions
- First Posted Date
- 2013-05-09
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 213
- Registration Number
- NCT01850602
A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
- First Posted Date
- 2013-04-17
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 161
- Registration Number
- NCT01833494
- Locations
- 🇯🇵
JAPAN, Multiple Locations, Japan
PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia
- Conditions
- Chronic Kidney Disease Requiring Hemodialysis
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-01-30
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 183
- Registration Number
- NCT01521494
- Locations
- 🇯🇵
Japan, Multiple Locations, Japan
A Drug-Drug Interaction Study of Digoxin and PA21
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2012-01-18
- Lead Sponsor
- Vifor Pharma
- Target Recruit Count
- 42
- Registration Number
- NCT01477411
- Locations
- 🇺🇸
ACRI - Phase 1, Anaheim, California, United States
A Drug-Drug Interaction Study of Warfarin and PA21
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2012-02-16
- Lead Sponsor
- Vifor Pharma
- Target Recruit Count
- 45
- Registration Number
- NCT01477424
- Locations
- 🇺🇸
PRA International - Clinical Pharmacology Center, Lenexa, Kansas, United States
Intravenous Versus Oral Iron in Late Pregnancy: Results of Treatment
- Conditions
- Pregnancy ComplicationsAnemia
- Interventions
- Drug: Ferli-6® (Continental Pharm co., ltd.)
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- Mahidol University
- Target Recruit Count
- 80
- Registration Number
- NCT00746551
- Locations
- 🇹🇭
Siriraj Hospital, Mahidol University, Bangkok, Thailand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.